APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acute Myeloid Leukemia Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Acute Myeloid Leukemia Drugs Market Analysis and Forecast 2026-2032

22 December 2025191 pages

Choose your research edition.

Industry ResearchAcute Myeloid Leukemia Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Myeloid Leukemia Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Acute Myeloid Leukemia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Myeloid Leukemia Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Myeloid Leukemia Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Acute Myeloid Leukemia Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Acute Myeloid Leukemia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Acute Myeloid Leukemia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Acute Myeloid Leukemia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Acute Myeloid Leukemia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Acute Myeloid Leukemia Drugs include Takeda Pharmaceuticals, Eisai, Novartis, Eli Lilly and Company, Sunesis Pharmaceuticals, Otsuka Holdings, Genzyme Corporation, Clavis Pharma and Cephalon, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Acute Myeloid Leukemia Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Acute Myeloid Leukemia Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Acute Myeloid Leukemia Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Acute Myeloid Leukemia Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Acute Myeloid Leukemia Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Acute Myeloid Leukemia Drugs sales, projected growth trends, production technology, application and end-user industry.

Acute Myeloid Leukemia Drugs Segment by Company

Takeda Pharmaceuticals

Eisai

Novartis

Eli Lilly and Company

Sunesis Pharmaceuticals

Otsuka Holdings

Genzyme Corporation

Clavis Pharma

Cephalon

Bristol Myers Squibb

Ambit Biosciences Corporation

Acute Myeloid Leukemia Drugs Segment by Type

Chemotherapy

Targeted Therapy

Other

Acute Myeloid Leukemia Drugs Segment by Application

Hospital

Clinic

Others

Acute Myeloid Leukemia Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Myeloid Leukemia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Myeloid Leukemia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Myeloid Leukemia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Acute Myeloid Leukemia Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Acute Myeloid Leukemia Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acute Myeloid Leukemia Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Acute Myeloid Leukemia Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Chemotherapy Major Manufacturers Table 3. Targeted Therapy Major Manufacturers Table 4. Other Major Manufacturers Table 5. Global Acute Myeloid Leukemia Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Manufacturers Table 7. Clinic Major Manufacturers Table 8. Others Major Manufacturers Table 9. Acute Myeloid Leukemia Drugs Industry Trends Table 10. Acute Myeloid Leukemia Drugs Industry Drivers Table 11. Acute Myeloid Leukemia Drugs Industry Opportunities and Challenges Table 12. Acute Myeloid Leukemia Drugs Industry Restraints Table 13. Global Acute Myeloid Leukemia Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Acute Myeloid Leukemia Drugs Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Acute Myeloid Leukemia Drugs Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Region (2021-2026) Table 17. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Region (2027-2032) Table 18. Global Acute Myeloid Leukemia Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 19. Global Acute Myeloid Leukemia Drugs Sales by Region (2021-2026) & (k units) Table 20. Global Acute Myeloid Leukemia Drugs Sales by Region (2027-2032) & (k units) Table 21. Global Acute Myeloid Leukemia Drugs Sales Market Share by Region (2021-2026) Table 22. Global Acute Myeloid Leukemia Drugs Sales Market Share by Region (2027-2032) Table 23. Global Acute Myeloid Leukemia Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Acute Myeloid Leukemia Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Acute Myeloid Leukemia Drugs Sales Market Share by Manufacturers (2021-2026) Table 27. Global Acute Myeloid Leukemia Drugs Sales Price (US$/unit) of Manufacturers (2021-2026) Table 28. Global Acute Myeloid Leukemia Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Acute Myeloid Leukemia Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Acute Myeloid Leukemia Drugs Manufacturers, Product Type & Application Table 31. Global Acute Myeloid Leukemia Drugs Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Acute Myeloid Leukemia Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Acute Myeloid Leukemia Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Acute Myeloid Leukemia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Acute Myeloid Leukemia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2021-2026) Table 38. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2027-2032) Table 39. Global Acute Myeloid Leukemia Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 40. Global Acute Myeloid Leukemia Drugs Sales by Type (2021-2026) & (k units) Table 41. Global Acute Myeloid Leukemia Drugs Sales by Type (2027-2032) & (k units) Table 42. Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2021-2026) Table 43. Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2027-2032) Table 44. Global Acute Myeloid Leukemia Drugs Price by Type (2021-2026) & (US$/unit) Table 45. Global Acute Myeloid Leukemia Drugs Price by Type (2027-2032) & (US$/unit) Table 46. Global Acute Myeloid Leukemia Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Acute Myeloid Leukemia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Acute Myeloid Leukemia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2021-2026) Table 50. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2027-2032) Table 51. Global Acute Myeloid Leukemia Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 52. Global Acute Myeloid Leukemia Drugs Sales by Application (2021-2026) & (k units) Table 53. Global Acute Myeloid Leukemia Drugs Sales by Application (2027-2032) & (k units) Table 54. Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2021-2026) Table 55. Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2027-2032) Table 56. Global Acute Myeloid Leukemia Drugs Price by Application (2021-2026) & (US$/unit) Table 57. Global Acute Myeloid Leukemia Drugs Price by Application (2027-2032) & (US$/unit) Table 58. Takeda Pharmaceuticals Company Information Table 59. Takeda Pharmaceuticals Business Overview Table 60. Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio Table 62. Takeda Pharmaceuticals Recent Development Table 63. Eisai Company Information Table 64. Eisai Business Overview Table 65. Eisai Acute Myeloid Leukemia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Eisai Acute Myeloid Leukemia Drugs Product Portfolio Table 67. Eisai Recent Development Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis Acute Myeloid Leukemia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Novartis Acute Myeloid Leukemia Drugs Product Portfolio Table 72. Novartis Recent Development Table 73. Eli Lilly and Company Company Information Table 74. Eli Lilly and Company Business Overview Table 75. Eli Lilly and Company Acute Myeloid Leukemia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Eli Lilly and Company Acute Myeloid Leukemia Drugs Product Portfolio Table 77. Eli Lilly and Company Recent Development Table 78. Sunesis Pharmaceuticals Company Information Table 79. Sunesis Pharmaceuticals Business Overview Table 80. Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio Table 82. Sunesis Pharmaceuticals Recent Development Table 83. Otsuka Holdings Company Information Table 84. Otsuka Holdings Business Overview Table 85. Otsuka Holdings Acute Myeloid Leukemia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Otsuka Holdings Acute Myeloid Leukemia Drugs Product Portfolio Table 87. Otsuka Holdings Recent Development Table 88. Genzyme Corporation Company Information Table 89. Genzyme Corporation Business Overview Table 90. Genzyme Corporation Acute Myeloid Leukemia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Genzyme Corporation Acute Myeloid Leukemia Drugs Product Portfolio Table 92. Genzyme Corporation Recent Development Table 93. Clavis Pharma Company Information Table 94. Clavis Pharma Business Overview Table 95. Clavis Pharma Acute Myeloid Leukemia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Clavis Pharma Acute Myeloid Leukemia Drugs Product Portfolio Table 97. Clavis Pharma Recent Development Table 98. Cephalon Company Information Table 99. Cephalon Business Overview Table 100. Cephalon Acute Myeloid Leukemia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Cephalon Acute Myeloid Leukemia Drugs Product Portfolio Table 102. Cephalon Recent Development Table 103. Bristol Myers Squibb Company Information Table 104. Bristol Myers Squibb Business Overview Table 105. Bristol Myers Squibb Acute Myeloid Leukemia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Bristol Myers Squibb Acute Myeloid Leukemia Drugs Product Portfolio Table 107. Bristol Myers Squibb Recent Development Table 108. Ambit Biosciences Corporation Company Information Table 109. Ambit Biosciences Corporation Business Overview Table 110. Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Product Portfolio Table 112. Ambit Biosciences Corporation Recent Development Table 113. North America Acute Myeloid Leukemia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 114. North America Acute Myeloid Leukemia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 115. North America Acute Myeloid Leukemia Drugs Sales by Type (2021-2026) & (k units) Table 116. North America Acute Myeloid Leukemia Drugs Sales by Type (2027-2032) & (k units) Table 117. North America Acute Myeloid Leukemia Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 118. North America Acute Myeloid Leukemia Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 119. North America Acute Myeloid Leukemia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 120. North America Acute Myeloid Leukemia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 121. North America Acute Myeloid Leukemia Drugs Sales by Application (2021-2026) & (k units) Table 122. North America Acute Myeloid Leukemia Drugs Sales by Application (2027-2032) & (k units) Table 123. North America Acute Myeloid Leukemia Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 124. North America Acute Myeloid Leukemia Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 125. North America Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. North America Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 127. North America Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 128. North America Acute Myeloid Leukemia Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 129. North America Acute Myeloid Leukemia Drugs Sales by Country (2021-2026) & (k units) Table 130. North America Acute Myeloid Leukemia Drugs Sales by Country (2027-2032) & (k units) Table 131. North America Acute Myeloid Leukemia Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 132. North America Acute Myeloid Leukemia Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 133. United States Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 134. Canada Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 135. Mexico Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 136. Europe Acute Myeloid Leukemia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 137. Europe Acute Myeloid Leukemia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 138. Europe Acute Myeloid Leukemia Drugs Sales by Type (2021-2026) & (k units) Table 139. Europe Acute Myeloid Leukemia Drugs Sales by Type (2027-2032) & (k units) Table 140. Europe Acute Myeloid Leukemia Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 141. Europe Acute Myeloid Leukemia Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 142. Europe Acute Myeloid Leukemia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 143. Europe Acute Myeloid Leukemia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 144. Europe Acute Myeloid Leukemia Drugs Sales by Application (2021-2026) & (k units) Table 145. Europe Acute Myeloid Leukemia Drugs Sales by Application (2027-2032) & (k units) Table 146. Europe Acute Myeloid Leukemia Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 147. Europe Acute Myeloid Leukemia Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 148. Europe Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Europe Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 150. Europe Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 151. Europe Acute Myeloid Leukemia Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 152. Europe Acute Myeloid Leukemia Drugs Sales by Country (2021-2026) & (k units) Table 153. Europe Acute Myeloid Leukemia Drugs Sales by Country (2027-2032) & (k units) Table 154. Europe Acute Myeloid Leukemia Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 155. Europe Acute Myeloid Leukemia Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 156. Germany Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 157. France Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 158. U.K. Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 159. Italy Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 160. Russia Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 161. Spain Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 162. Netherlands Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 163. Switzerland Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 164. Sweden Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 165. Poland Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 166. China Acute Myeloid Leukemia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 167. China Acute Myeloid Leukemia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 168. China Acute Myeloid Leukemia Drugs Sales by Type (2021-2026) & (k units) Table 169. China Acute Myeloid Leukemia Drugs Sales by Type (2027-2032) & (k units) Table 170. China Acute Myeloid Leukemia Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 171. China Acute Myeloid Leukemia Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 172. China Acute Myeloid Leukemia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 173. China Acute Myeloid Leukemia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 174. China Acute Myeloid Leukemia Drugs Sales by Application (2021-2026) & (k units) Table 175. China Acute Myeloid Leukemia Drugs Sales by Application (2027-2032) & (k units) Table 176. China Acute Myeloid Leukemia Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 177. China Acute Myeloid Leukemia Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 178. Asia Acute Myeloid Leukemia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 179. Asia Acute Myeloid Leukemia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 180. Asia Acute Myeloid Leukemia Drugs Sales by Type (2021-2026) & (k units) Table 181. Asia Acute Myeloid Leukemia Drugs Sales by Type (2027-2032) & (k units) Table 182. Asia Acute Myeloid Leukemia Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 183. Asia Acute Myeloid Leukemia Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 184. Asia Acute Myeloid Leukemia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 185. Asia Acute Myeloid Leukemia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 186. Asia Acute Myeloid Leukemia Drugs Sales by Application (2021-2026) & (k units) Table 187. Asia Acute Myeloid Leukemia Drugs Sales by Application (2027-2032) & (k units) Table 188. Asia Acute Myeloid Leukemia Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 189. Asia Acute Myeloid Leukemia Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 190. Asia Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 191. Asia Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 192. Asia Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 193. Asia Acute Myeloid Leukemia Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 194. Asia Acute Myeloid Leukemia Drugs Sales by Country (2021-2026) & (k units) Table 195. Asia Acute Myeloid Leukemia Drugs Sales by Country (2027-2032) & (k units) Table 196. Asia Acute Myeloid Leukemia Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 197. Asia Acute Myeloid Leukemia Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 198. Japan Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 199. South Korea Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 200. India Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 201. Australia Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 202. Taiwan Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 203. Southeast Asia Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 204. SAMEA Acute Myeloid Leukemia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 205. SAMEA Acute Myeloid Leukemia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 206. SAMEA Acute Myeloid Leukemia Drugs Sales by Type (2021-2026) & (k units) Table 207. SAMEA Acute Myeloid Leukemia Drugs Sales by Type (2027-2032) & (k units) Table 208. SAMEA Acute Myeloid Leukemia Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 209. SAMEA Acute Myeloid Leukemia Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 210. SAMEA Acute Myeloid Leukemia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 211. SAMEA Acute Myeloid Leukemia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 212. SAMEA Acute Myeloid Leukemia Drugs Sales by Application (2021-2026) & (k units) Table 213. SAMEA Acute Myeloid Leukemia Drugs Sales by Application (2027-2032) & (k units) Table 214. SAMEA Acute Myeloid Leukemia Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 215. SAMEA Acute Myeloid Leukemia Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 216. SAMEA Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 217. SAMEA Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 218. SAMEA Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 219. SAMEA Acute Myeloid Leukemia Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 220. SAMEA Acute Myeloid Leukemia Drugs Sales by Country (2021-2026) & (k units) Table 221. SAMEA Acute Myeloid Leukemia Drugs Sales by Country (2027-2032) & (k units) Table 222. SAMEA Acute Myeloid Leukemia Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 223. SAMEA Acute Myeloid Leukemia Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 224. Brazil Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 225. Argentina Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 226. Chile Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 227. Colombia Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 228. Peru Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 229. Saudi Arabia Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 230. Israel Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 231. UAE Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 232. Turkey Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 233. Iran Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 234. Egypt Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Table 235. Key Raw Materials Table 236. Raw Materials Key Suppliers Table 237. Acute Myeloid Leukemia Drugs Distributors List Table 238. Acute Myeloid Leukemia Drugs Customers List Table 239. Research Programs/Design for This Report Table 240. Authors List of This Report Table 241. Secondary Sources Table 242. Primary Sources List of Figures Figure 1. Acute Myeloid Leukemia Drugs Image Figure 2. Global Acute Myeloid Leukemia Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Myeloid Leukemia Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Chemotherapy Image Figure 5. Targeted Therapy Image Figure 6. Other Image Figure 7. Global Acute Myeloid Leukemia Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Acute Myeloid Leukemia Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Clinic Image Figure 11. Others Image Figure 12. Global Acute Myeloid Leukemia Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Acute Myeloid Leukemia Drugs Revenue (2021-2032) & (US$ Million) Figure 14. Global Acute Myeloid Leukemia Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Region (2021-2032) Figure 17. Global Acute Myeloid Leukemia Drugs Sales (2021-2032) & (k units) Figure 18. Global Acute Myeloid Leukemia Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 19. Global Acute Myeloid Leukemia Drugs Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Acute Myeloid Leukemia Drugs Sales YoY (2021-2032) & (k units) Figure 21. Europe Acute Myeloid Leukemia Drugs Sales YoY (2021-2032) & (k units) Figure 22. China Acute Myeloid Leukemia Drugs Sales YoY (2021-2032) & (k units) Figure 23. Asia (Excluding China) Acute Myeloid Leukemia Drugs Sales YoY (2021-2032) & (k units) Figure 24. South America, Middle East and Africa Acute Myeloid Leukemia Drugs Sales YoY (2021-2032) & (k units) Figure 25. Global Acute Myeloid Leukemia Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Acute Myeloid Leukemia Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Acute Myeloid Leukemia Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2021-2032) Figure 31. Global Acute Myeloid Leukemia Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 32. Global Acute Myeloid Leukemia Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2021-2032) Figure 34. Global Acute Myeloid Leukemia Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2021-2032) Figure 37. Global Acute Myeloid Leukemia Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 38. Global Acute Myeloid Leukemia Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2021-2032) Figure 40. North America Acute Myeloid Leukemia Drugs Revenue Share by Type (2021-2032) Figure 41. North America Acute Myeloid Leukemia Drugs Sales Share by Type (2021-2032) Figure 42. North America Acute Myeloid Leukemia Drugs Revenue Share by Application (2021-2032) Figure 43. North America Acute Myeloid Leukemia Drugs Sales Share by Application (2021-2032) Figure 44. North America Acute Myeloid Leukemia Drugs Revenue Share by Country (2021-2032) Figure 45. North America Acute Myeloid Leukemia Drugs Sales Share by Country (2021-2032) Figure 46. Europe Acute Myeloid Leukemia Drugs Revenue Share by Type (2021-2032) Figure 47. Europe Acute Myeloid Leukemia Drugs Sales Share by Type (2021-2032) Figure 48. Europe Acute Myeloid Leukemia Drugs Revenue Share by Application (2021-2032) Figure 49. Europe Acute Myeloid Leukemia Drugs Sales Share by Application (2021-2032) Figure 50. Europe Acute Myeloid Leukemia Drugs Revenue Share by Country (2021-2032) Figure 51. Europe Acute Myeloid Leukemia Drugs Sales Share by Country (2021-2032) Figure 52. China Acute Myeloid Leukemia Drugs Revenue Share by Type (2021-2032) Figure 53. China Acute Myeloid Leukemia Drugs Sales Share by Type (2021-2032) Figure 54. China Acute Myeloid Leukemia Drugs Revenue Share by Application (2021-2032) Figure 55. China Acute Myeloid Leukemia Drugs Sales Share by Application (2021-2032) Figure 56. Asia Acute Myeloid Leukemia Drugs Revenue Share by Type (2021-2032) Figure 57. Asia Acute Myeloid Leukemia Drugs Sales Share by Type (2021-2032) Figure 58. Asia Acute Myeloid Leukemia Drugs Revenue Share by Application (2021-2032) Figure 59. Asia Acute Myeloid Leukemia Drugs Sales Share by Application (2021-2032) Figure 60. Asia Acute Myeloid Leukemia Drugs Revenue Share by Country (2021-2032) Figure 61. Asia Acute Myeloid Leukemia Drugs Sales Share by Country (2021-2032) Figure 62. SAMEA Acute Myeloid Leukemia Drugs Revenue Share by Type (2021-2032) Figure 63. SAMEA Acute Myeloid Leukemia Drugs Sales Share by Type (2021-2032) Figure 64. SAMEA Acute Myeloid Leukemia Drugs Revenue Share by Application (2021-2032) Figure 65. SAMEA Acute Myeloid Leukemia Drugs Sales Share by Application (2021-2032) Figure 66. SAMEA Acute Myeloid Leukemia Drugs Revenue Share by Country (2021-2032) Figure 67. SAMEA Acute Myeloid Leukemia Drugs Sales Share by Country (2021-2032) Figure 68. Acute Myeloid Leukemia Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Acute Myeloid Leukemia Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Targeted Therapy
  • Other
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Takeda Pharmaceuticals
  • Eisai
  • Novartis
  • Eli Lilly and Company
  • Sunesis Pharmaceuticals
  • Otsuka Holdings
  • Genzyme Corporation
  • Clavis Pharma
  • Cephalon
  • Bristol Myers Squibb
  • Ambit Biosciences Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Acute Myeloid Leukemia Drugs Market by Type
  3. 1.2.1 Global Acute Myeloid Leukemia Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Chemotherapy
  5. 1.2.3 Targeted Therapy
  6. 1.2.4 Other
  7. 1.3 Acute Myeloid Leukemia Drugs Market by Application
  8. 1.3.1 Global Acute Myeloid Leukemia Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Clinic
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Acute Myeloid Leukemia Drugs Market Dynamics
  1. 2.1 Acute Myeloid Leukemia Drugs Industry Trends
  2. 2.2 Acute Myeloid Leukemia Drugs Industry Drivers
  3. 2.3 Acute Myeloid Leukemia Drugs Industry Opportunities and Challenges
  4. 2.4 Acute Myeloid Leukemia Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Acute Myeloid Leukemia Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Acute Myeloid Leukemia Drugs Revenue by Region
  3. 3.2.1 Global Acute Myeloid Leukemia Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Acute Myeloid Leukemia Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Acute Myeloid Leukemia Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Acute Myeloid Leukemia Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Acute Myeloid Leukemia Drugs Sales by Region
  9. 3.4.1 Global Acute Myeloid Leukemia Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Acute Myeloid Leukemia Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Acute Myeloid Leukemia Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Acute Myeloid Leukemia Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Acute Myeloid Leukemia Drugs Revenue by Manufacturers
  2. 4.1.1 Global Acute Myeloid Leukemia Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Acute Myeloid Leukemia Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Acute Myeloid Leukemia Drugs Sales by Manufacturers
  6. 4.2.1 Global Acute Myeloid Leukemia Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Acute Myeloid Leukemia Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Acute Myeloid Leukemia Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Acute Myeloid Leukemia Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Acute Myeloid Leukemia Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Acute Myeloid Leukemia Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Acute Myeloid Leukemia Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Acute Myeloid Leukemia Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Acute Myeloid Leukemia Drugs Market CR5 and HHI
  16. 4.8.2 2025 Acute Myeloid Leukemia Drugs Tier 1, Tier 2, and Tier 3
5 Acute Myeloid Leukemia Drugs Market by Type
  1. 5.1 Global Acute Myeloid Leukemia Drugs Revenue by Type
  2. 5.1.1 Global Acute Myeloid Leukemia Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Acute Myeloid Leukemia Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Acute Myeloid Leukemia Drugs Sales by Type
  6. 5.2.1 Global Acute Myeloid Leukemia Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Acute Myeloid Leukemia Drugs Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Acute Myeloid Leukemia Drugs Price by Type
6 Acute Myeloid Leukemia Drugs Market by Application
  1. 6.1 Global Acute Myeloid Leukemia Drugs Revenue by Application
  2. 6.1.1 Global Acute Myeloid Leukemia Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Acute Myeloid Leukemia Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Acute Myeloid Leukemia Drugs Sales by Application
  6. 6.2.1 Global Acute Myeloid Leukemia Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Acute Myeloid Leukemia Drugs Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Acute Myeloid Leukemia Drugs Price by Application
7 Company Profiles
  1. 7.1 Takeda Pharmaceuticals
  2. 7.1.1 Takeda Pharmaceuticals Company Information
  3. 7.1.2 Takeda Pharmaceuticals Business Overview
  4. 7.1.3 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio
  6. 7.1.5 Takeda Pharmaceuticals Recent Developments
  7. 7.2 Eisai
  8. 7.2.1 Eisai Company Information
  9. 7.2.2 Eisai Business Overview
  10. 7.2.3 Eisai Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Eisai Acute Myeloid Leukemia Drugs Product Portfolio
  12. 7.2.5 Eisai Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Acute Myeloid Leukemia Drugs Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Eli Lilly and Company
  20. 7.4.1 Eli Lilly and Company Company Information
  21. 7.4.2 Eli Lilly and Company Business Overview
  22. 7.4.3 Eli Lilly and Company Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Eli Lilly and Company Acute Myeloid Leukemia Drugs Product Portfolio
  24. 7.4.5 Eli Lilly and Company Recent Developments
  25. 7.5 Sunesis Pharmaceuticals
  26. 7.5.1 Sunesis Pharmaceuticals Company Information
  27. 7.5.2 Sunesis Pharmaceuticals Business Overview
  28. 7.5.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio
  30. 7.5.5 Sunesis Pharmaceuticals Recent Developments
  31. 7.6 Otsuka Holdings
  32. 7.6.1 Otsuka Holdings Company Information
  33. 7.6.2 Otsuka Holdings Business Overview
  34. 7.6.3 Otsuka Holdings Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Otsuka Holdings Acute Myeloid Leukemia Drugs Product Portfolio
  36. 7.6.5 Otsuka Holdings Recent Developments
  37. 7.7 Genzyme Corporation
  38. 7.7.1 Genzyme Corporation Company Information
  39. 7.7.2 Genzyme Corporation Business Overview
  40. 7.7.3 Genzyme Corporation Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Genzyme Corporation Acute Myeloid Leukemia Drugs Product Portfolio
  42. 7.7.5 Genzyme Corporation Recent Developments
  43. 7.8 Clavis Pharma
  44. 7.8.1 Clavis Pharma Company Information
  45. 7.8.2 Clavis Pharma Business Overview
  46. 7.8.3 Clavis Pharma Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Clavis Pharma Acute Myeloid Leukemia Drugs Product Portfolio
  48. 7.8.5 Clavis Pharma Recent Developments
  49. 7.9 Cephalon
  50. 7.9.1 Cephalon Company Information
  51. 7.9.2 Cephalon Business Overview
  52. 7.9.3 Cephalon Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Cephalon Acute Myeloid Leukemia Drugs Product Portfolio
  54. 7.9.5 Cephalon Recent Developments
  55. 7.10 Bristol Myers Squibb
  56. 7.10.1 Bristol Myers Squibb Company Information
  57. 7.10.2 Bristol Myers Squibb Business Overview
  58. 7.10.3 Bristol Myers Squibb Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Bristol Myers Squibb Acute Myeloid Leukemia Drugs Product Portfolio
  60. 7.10.5 Bristol Myers Squibb Recent Developments
  61. 7.11 Ambit Biosciences Corporation
  62. 7.11.1 Ambit Biosciences Corporation Company Information
  63. 7.11.2 Ambit Biosciences Corporation Business Overview
  64. 7.11.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Product Portfolio
  66. 7.11.5 Ambit Biosciences Corporation Recent Developments
8 North America
  1. 8.1 North America Acute Myeloid Leukemia Drugs Market Size by Type
  2. 8.1.1 North America Acute Myeloid Leukemia Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Acute Myeloid Leukemia Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Acute Myeloid Leukemia Drugs Price by Type (2021-2032)
  5. 8.2 North America Acute Myeloid Leukemia Drugs Market Size by Application
  6. 8.2.1 North America Acute Myeloid Leukemia Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Acute Myeloid Leukemia Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Acute Myeloid Leukemia Drugs Price by Application (2021-2032)
  9. 8.3 North America Acute Myeloid Leukemia Drugs Market Size by Country
  10. 8.3.1 North America Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Acute Myeloid Leukemia Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Acute Myeloid Leukemia Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Acute Myeloid Leukemia Drugs Market Size by Type
  2. 9.1.1 Europe Acute Myeloid Leukemia Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Acute Myeloid Leukemia Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Acute Myeloid Leukemia Drugs Price by Type (2021-2032)
  5. 9.2 Europe Acute Myeloid Leukemia Drugs Market Size by Application
  6. 9.2.1 Europe Acute Myeloid Leukemia Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Acute Myeloid Leukemia Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Acute Myeloid Leukemia Drugs Price by Application (2021-2032)
  9. 9.3 Europe Acute Myeloid Leukemia Drugs Market Size by Country
  10. 9.3.1 Europe Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Acute Myeloid Leukemia Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Acute Myeloid Leukemia Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Acute Myeloid Leukemia Drugs Market Size by Type
  2. 10.1.1 China Acute Myeloid Leukemia Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Acute Myeloid Leukemia Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Acute Myeloid Leukemia Drugs Price by Type (2021-2032)
  5. 10.2 China Acute Myeloid Leukemia Drugs Market Size by Application
  6. 10.2.1 China Acute Myeloid Leukemia Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Acute Myeloid Leukemia Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Acute Myeloid Leukemia Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Acute Myeloid Leukemia Drugs Market Size by Type
  2. 11.1.1 Asia Acute Myeloid Leukemia Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Acute Myeloid Leukemia Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Acute Myeloid Leukemia Drugs Price by Type (2021-2032)
  5. 11.2 Asia Acute Myeloid Leukemia Drugs Market Size by Application
  6. 11.2.1 Asia Acute Myeloid Leukemia Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Acute Myeloid Leukemia Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Acute Myeloid Leukemia Drugs Price by Application (2021-2032)
  9. 11.3 Asia Acute Myeloid Leukemia Drugs Market Size by Country
  10. 11.3.1 Asia Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Acute Myeloid Leukemia Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Acute Myeloid Leukemia Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Acute Myeloid Leukemia Drugs Market Size by Type
  2. 12.1.1 SAMEA Acute Myeloid Leukemia Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Acute Myeloid Leukemia Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Acute Myeloid Leukemia Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Acute Myeloid Leukemia Drugs Market Size by Application
  6. 12.2.1 SAMEA Acute Myeloid Leukemia Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Acute Myeloid Leukemia Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Acute Myeloid Leukemia Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Acute Myeloid Leukemia Drugs Market Size by Country
  10. 12.3.1 SAMEA Acute Myeloid Leukemia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Acute Myeloid Leukemia Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Acute Myeloid Leukemia Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Acute Myeloid Leukemia Drugs Value Chain Analysis
  2. 13.1.1 Acute Myeloid Leukemia Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Acute Myeloid Leukemia Drugs Production Mode & Process
  6. 13.2 Acute Myeloid Leukemia Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Acute Myeloid Leukemia Drugs Distributors
  9. 13.2.3 Acute Myeloid Leukemia Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst